Qidni Labs

Buffalo, New York, United States

Qidni works on implantable artificial kidneys for three million patients with kidney failure (end stage renal disease). Over two million patients around the world suffer from End Stage Renal Disease (ESRD). Patients’ survival depends on dialysis, a renal replacement therapy that they undergo until they receive a kidney transplant. The survival rate of patients under dialysis is less than 40% in 5 years. On average, a year of dialysis of each patient costs upwards of $82,000 in the United States. A year of dialysis of each patient may cost $82,000 in the United States. Patients endure a lot more hardships due to complications and lifestyle restrictions. Studies show that longer treatment times can potentially be associated with prolonged survival. We have working lab prototypes. Animal studies are lined up for the first half of 2016. Our technology is patent pending. We are working on an implantable renal replacement therapy. Our device would reduce several costs associated with dialysis equipment, caregivers and insurance providers. We are creating an opportunity for patients to have access to renal replacement therapy continuously and at all times.